Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of BAY 2413555 in healthy male volunteers
NL-OMON54965Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in heart failure (HF) comparing BAY 2413555 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Aug 2019; status: active, not recruiting.
02
Drugs
BAY2413555
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON54965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54965.